FDA, EMA put a star CAR-T from blue­bird and Cel­gene on the VIP list

Dur­ing the last AS­CO blue­bird bio and its part­ners at Cel­gene an­gled in­to cen­ter stage with an up­date on their BC­MA-tar­get­ing CAR-T drug bb2121 for mul­ti­ple myelo­ma that wowed the can­cer crowd.

The FDA as well as Eu­ro­pean reg­u­la­tors were pay­ing at­ten­tion. To­day the two com­pa­nies an­nounced that both groups had put the pro­gram on their VIP list, with a break­through ther­a­py des­ig­na­tion right along­side PRIME sta­tus.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.